The global DNA sequencing market is projected to reach USD 40.02 billion by 2031, driven by declining sequencing costs, expanding clinical applications in oncology and rare diseases, and growing ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results